

Ulrich G. Steidl – Biosketch

Education

1993-2000 M.D., Ph.D., University of Heidelberg Medical School and German Cancer Research Center (DKFZ), Heidelberg, Germany

Positions and Employment

2000-2003 Resident Physician, Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Medical Center, Düsseldorf, Germany

2003-2006 Research Fellow in Medicine, Harvard Stem Cell Institute and Beth Israel Deaconess Medical Center, Boston, MA

2006-2008 Instructor in Medicine, Harvard Medical School, Boston, MA

2008-2013 Assistant Professor of Cell Biology and Medicine, Albert Einstein College of Medicine

2011-present Director, Stem Cell Isolation & Xenotransplantation Facility, Gottesman Institute for Stem Cell and Regenerative Medicine Research

2013-2016 Associate Professor of Cell Biology, and of Medicine (Oncology)

2013-present Associate Chair for Translational Research, Department of Medicine (Oncology)

2013-present Scientific Director, Division of Hemato-Oncology

2014-present Program Leader, “Stem Cells, Differentiation, and Cancer” Program, Albert Einstein Cancer Center

2016-2017 Professor of Cell Biology, and of Medicine (Oncology)

2017-present Professor with tenure, Departments of Cell Biology, and of Medicine

Awards and Honors:

1994-2000 Medical School Scholarship, National German Scholarship Foundation

2002 Young Masters Award, German and Austrian Societies of Hematology/Oncology

2002 Chugai Science Award for outstanding merit in the field of clinical and experimental stem cell and bone marrow transplantation

2004-2005 Postdoctoral Fellowship, Dr. Mildred Scheel Foundation for Cancer Research

2005 Young Masters Award, German, Austrian and Swiss Societies of Hematology

2005 Merit Award, American Society of Hematology

2008 Howard Temin Award in Cancer Research, NIH/NCI

2009 Diane and Arthur B. Belfer Faculty Scholar in Cancer Research, Albert Einstein College

2010 Medical Research Award, Gabrielle’s Angel Foundation

2012 Research Award, Feldstein Medical Foundation

2014 Research Scholar, Leukemia & Lymphoma Society

2015 Elected Member, Interurban Clinical Club (Founder: Sir William Osler)

2016 Elected Member, American Society for Clinical Investigation (ASCI)

2017-present Senior Editor, *Clinical Cancer Research* (AACR)

2017-present Editorial Board, *The Journal of Experimental Medicine* (Rockefeller University Press)

2017-2022 Board of Directors, International Society of Experimental Hematology (ISEH)

2019 Julius Marmur Award for Excellence in Graduate Student Mentoring

Other Experience and Professional Memberships

Society Memberships: American Society of Hematology (since 2004), European Hematology Association (since 2007), Eastern Cooperative Oncology Group (since 2008), American Association for Cancer Research (AACR) (since 2013), International Society for Experimental Hematology (ISEH) (since 2013)

Ad-hoc Reviewer for Funding Agencies: Leukemia & Lymphoma Society, TRP (2014-present); NIH/NCI P01 study section (2014); Department of Defense (2014); Leukemia & Lymphoma Society, Career Development Program (2015-present); NIH CAMP study section (2013-2016); NIH MCH study section (2014-2016); ASH, Scholar Award study section (2015-present); NIH, Lasker Research Scholars Program (2017)

2010-present Member, Medical Advisory Board, Leukemia Research Foundation

2010-2013 Member, Laboratory Science Advisory Committee (LabSAC), ECOG

2013-present Member, ECOG-ACRIN, Laboratory Science & Pathology Review Committee

2015-present Co-Organizer, Workshop on Myeloid Development, American Society of Hematology (ASH)

2016-2022 Appointed Member, National Institutes of Health, CAMP study section

2017-2021 Member, Board of Directors, ISEH

2018-2022 Member, Scientific Committee on Myeloid Neoplasia, ASH

Contribution to Science (selected publications out of a total of 118).

Functional and mechanistic study of (pre-)leukemic stem cells in myeloid malignancies.

- a. Chen J, Kao YR, Sun D, Todorova TI, Reynolds D, Narayanagari SR, Montagna C, Will B, Verma A*, Steidl U*. MDS progression to AML at the stem cell level. *Nat Med*. 2019; 25:103-110.
- b. Stanley RF*, Piszczatowski RT*, Bartholdy B, Mitchell K, McKimpson WM, Narayanagari SR, Walter D, Todorova TI, Hirsch C, Makishima H, Will B, McMahon C, Gritsman K, Maciejewski JP, Kitsis RN, Steidl U. A myeloid tumor suppressor role for nucleolar protein 3 (NOL3). *J Exp Med*. 2017; 214:753-771.
- c. Will B*, Vogler TO*, Narayanagari S, Bartholdy B, Todorova TI, da Silva Ferreira M, Chen J, Yu Y, Mayer J, Barreyro L, Carvajal L, Ben Neriah D, Roth M, van Oers J, Schaetzlein S, McMahon C, Edelmann W, Verma A, Steidl U. Minimal PU.1 Reduction Induces a Preleukemic State and Promotes Development of Acute Myeloid Leukemia. *Nat Med*. 2015; 21:1172-81.
- d. Will B, Vogler TO, Bartholdy B, Garrett-Bakelman F, Mayer J, Barreyro L, Pandolfi A, Todorova TI, Okoye-Okafor UC, Stanley RF, Bhagat TD, Verma A, Figueroa ME, Melnick A, Roth M, Steidl U. Satb1 regulates hematopoietic stem cell self-renewal by promoting quiescence and repressing differentiation commitment. *Nat Immunol*. 2013; 14:437-45.
- e. Kawahara M*, Pandolfi A*, Bartholdy B*, Barreyro L, Will B, Roth M, Okoye-Okafor UC, Todorova TI, Figueroa ME, Melnick A, Mitsiades CS, Steidl U. H2.0-like homeobox (HLX) regulates early hematopoiesis and promotes acute myeloid leukemia. *Cancer Cell*. 2012; 22:194-208.

Target identification and functional and mechanistic validation at the stem cell level in MDS and AML.

- a. Mitchell K, Barreyro L, Todorova TI, Taylor SJ, Antony-Debré I, Narayanagari SR, Carvajal LA, Leite J, Piperdi Z, Pendurti G, Mantzaris I, Paietta E, Verma A, Gritsman K, Steidl U. IL1RAP potentiates multiple oncogenic signaling pathways in AML. *J Exp Med*. 2018; 215:1709-1727.
- b. Pandolfi A*, Stanley RF*, Yu Y, Bartholdy B, Pendurti G, Gritsman K, Boultonwood J, Chernoff J, Verma A, Steidl U. PAK1 is a Therapeutic Target in Acute Myeloid Leukemia and Myelodysplastic Syndrome. *Blood*. 2015; 126:1118-1127.
- c. Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultonwood J, Paietta E, Ketterling RP, Cripe L, Fernandez HF, Greenberg PL, Tallman MS, Steidl C, Mitsiades CS, Verma A, Steidl U. Overexpression of interleukin 1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. *Blood*. 2012; 120:1290-1298
- d. Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C, Tamari R, Yu Y, Bhagat T, Bhattacharya S, Barreyro L, Heuck C, Mo Y, Parekh S, McMahon C, Pellagatti A, Boultonwood J, Montagna C, Silverman L, Maciejewski J, Grealley J, Ye BH, List A, Steidl C, Steidl U*, Verma A*. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage specific expansion and harbor genetic and epigenetic alterations. *Blood*. 2012; 120: 2076-86. * co-corresponding authors

Preclinical study of novel agents in MDS and AML.

- a. Carvajal LA, Ben-Neriah D, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, Narayanagari SR, Wheat JC, Todorova TI, Mitchell KM, Kenworthy C, Guerlavais V, Annis DA, Bartholdy B, Will B, Anampa JD, Mantzaris I, Aivado M, Singer RH, Coleman RA, Verma A, Steidl U. Dual inhibition of MDMX and MDM2 as a Therapeutic Strategy in Leukemia. *Sci Transl Med*. 2018; 10:eaa03003
- b. Antony-Debré I, Paul A, Leite J, Mitchell K, Kim HM, Carvajal LA, Todorova TI, Huang K, Kumar A, Farahat AA, Bartholdy B, Narayanagari SR, Chen J, Ambesi-Impiombato A, Ferrando AA, Mantzaris I, Gavathiotis E, Verma A, Will B, Boykin DW, Wilson WD, Poon GMK, Steidl U. Inhibition of the myeloid master regulator PU.1 as a therapeutic strategy in acute myeloid leukemia. *J Clin Invest*. 2017; 127:4297-4313
- c. Okoye-Okafor UC, Bartholdy B, Cartier J, Gao EN, Pietrak B, Rendina AR, Rominger C, Quinn C, Smallwood A, Wiggall KJ, Reif AJ, Schmidt SJ, Qi H, Zhao H, Joberty G, Faeltsh-Savitski M, Bantscheff M, Drewes G, Duraiswami C, Brady P, Groy A, Narayanagari SR, Antony-Debre I, Mitchell K, Wang HR, Kao YR, Christopheit M, Carvajal L, Barreyro L, Paietta E, Makishima H, Will B, Concha N, Adams ND, Schwartz B, McCabe MT, Maciejewski J, Verma A, Steidl U. Novel IDH1 Mutant Inhibitors for Treatment of Acute Myeloid Leukemia. *Nat Chem Biol*. 2015; 11:878-86
- d. Roth M, Will B, Simkin G, Rao S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. *Blood*. 2012; 120(2):386-394.
- e. Will B, Kawahara M, Luciano JP, Bruns I, Parekh S, Erickson-Miller CL, Aivado MA, Verma A, Steidl U. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. *Blood*. 2009; 114:3899-3908.